CollPlant Biotechnologies Ltd
CLGNNasdaq
$0.34
↓ -1.3%Jul 17 close · end-of-day
Price
1Y↓ -81.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.1M
Enterprise Value
-$7.3M
P/E
—
P/S
1.7
P/B
0.3
EV/EBITDA
—
PEG
—
FCF Yield
-231.1%
Dividend Yield
—
Revenue (TTM)
$2.4M
Net Income (TTM)
-$11.5M
Free Cash Flow (TTM)
-$9.4M
Gross Margin
64.8%
Operating Margin
-484.3%
Net Margin
-484.6%
ROE
-91.9%
ROIC
-847.0%
Debt / Equity
—
Net Cash
$11.4M
Return 1Y
-81.6%
Company profile
CollPlant Biotechnologies Ltd. focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie.
- CEO
- Yehiel Tal
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 70
- Website
- collplant.com
Earnings
CLGN Q 2025 Earnings
Period ends 2025-06-30
MetricActualYoY
Revenue$179,000.00↓ -28.1%
Diluted EPS$0.28↓ -24.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.1M | $15.6M | $299,000.00 | $11.0M | $515,000.00 | $2.4M |
| Gross profit | $3.1M | $13.6M | -$101,000.00 | $9.0M | -$1.1M | $1.5M |
| Operating income | -$5.6M | $65,000.00 | -$17.1M | -$7.5M | -$17.3M | -$11.5M |
| Net income | -$5.8M | $237,000.00 | -$16.9M | -$7.0M | -$16.6M | -$11.5M |
| Diluted EPS | -$0.84 | $0.02 | -$1.53 | -$0.62 | -$1.45 | -$0.94 |
| Operating cash flow | -$4.5M | $2.5M | -$13.7M | -$2.8M | -$14.1M | -$9.4M |
| Free cash flow | -$4.9M | $1.1M | -$15.0M | -$3.7M | -$14.6M | -$9.4M |
| Gross margin | 51.1% | 87.2% | -33.8% | 81.8% | -215.5% | 64.8% |
| Operating margin | -91.2% | 0.4% | -5718.1% | -68.5% | -3349.7% | -484.3% |
| Net margin | -94.1% | 1.5% | -5660.5% | -64.0% | -3225.0% | -484.6% |
| Line item | Q2 '21 | Q2 '22 | Q2 '23 | Q '24 | Q '25 |
|---|---|---|---|---|---|
| Revenue | $691,000.00 | $66,000.00 | $10.2M | $249,000.00 | $179,000.00 |
| Gross profit | $262,000.00 | $23,000.00 | $9.6M | -$287,000.00 | -$7,000.00 |
| Operating income | -$3.1M | -$4.2M | $5.7M | -$4.4M | -$3.2M |
| Net income | -$3.0M | -$4.3M | $5.8M | -$4.2M | -$3.3M |
| Diluted EPS | -$0.30 | -$0.39 | $0.49 | $0.37 | $0.28 |
| Operating cash flow | — | — | — | — | — |
| Free cash flow | — | — | — | — | — |
| Gross margin | 37.9% | 34.8% | 94.0% | -115.3% | -3.9% |
| Operating margin | -443.3% | -6340.9% | 55.7% | -1769.5% | -1775.4% |
| Net margin | -439.7% | -6492.4% | 56.6% | -1690.8% | -1869.8% |
Company news
Jun 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.